Maternal-Fetal Health
Preeclampsia affects both mother and fetus and is linked to long-term cardiovascular and developmental risks. Many at-risk pregnancies go undetected.
aitios® NIPPT - Lead Program
One Test for Two Patients.
Our lead program pioneers the development of the world's first integrated first-trimester Non-Invasive Prenatal and Preeclampsia Test (NIPPT) for screening and risk assessment from a standard blood sample, expanding the clinical utility of existing testing infrastructure.
Clinical Application
Preeclampsia Risk Screening.
Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. Incidence is rising, creating a massive health and economic burden.
Preterm Preeclampsia
Occurs before 37 weeks and carries high risk for severe complications and premature delivery. Early identification enables preventive treatment before week 16.
Term Preeclampsia
Occurs at or after 37 weeks, increasing maternal complications and likelihood of intervention. Risk can be managed with close monitoring and delivery planning.
Patient Benefit
Sample to Insight.
1st Trimester
Simple Blood Draw
2nd & 3rd Trimester
Personalized Care
Lifelong
Maternal-Fetal Health
Development Roadmap
One Platform for Maternal-Fetal Health.
Aitiologic's platform is designed to extend beyond preeclampsia - enabling a unified blood test for maternal-fetal health, including gestational diabetes and other pregnancy-related conditions, with future applications in oncology and immune-mediated disease.
aitios® NIPPT is currently under development and available for research use only (RUO) to early access partners.